Bausch Health Companies Inc. (BHC) 2002 Q4 法說會逐字稿

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Good day everyone and welcome to the ICN Pharmaceuticals fourth quarter and year end 2002 conference call. Today's call is being recorded. At this time for opening remarks and introductions, I would now like to turn the conference over to Mr. Greg Keever, Executive Vice President, General Counsel, and Corporate Secretary for ICN. Please go ahead, sir.

    各位大家好,歡迎參加 ICN 製藥公司 2002 年第四季及年度結束電話會議。今天的電話會議將被錄音。現在進行開場致詞與介紹,我想把會議交給 ICN 的執行副總裁、總法律顧問兼公司秘書 Greg Keever 先生。先生,請開始。

  • - Executive Vice President General Counsel and Secretary

    - Executive Vice President General Counsel and Secretary

  • Good morning and welcome to today's call. Before we begin the call, I would like to read to you the Safe Harbor statement under the Private Securities Litigation Reform Act of 1995.

    各位早安,歡迎參加今天的電話會議。在我們開始之前,我想向各位宣讀 1995 年《私人證券訴訟改革法》下的「安全港」聲明。

  • This presentation contains forward-looking statements that involve risks and uncertainties, including but not limited to projections of future sales, royalty income, operating income, returns on invested assets, regulatory approval processes, competition from generic products, market place acceptance of the company's products, success of the company's strategic repositioning initiatives and the ability of management to execute them, success of the company's ongoing inventory reduction program and other cost reduction measures, and other risks detailed from time to time in the company's Securities and Exchange Commission filings.

    本簡報包含前瞻性陳述,涉及風險與不確定性,包括但不限於:對未來銷售、權利金收入、營業利益、投資資產報酬、法規核准流程、學名藥競爭、市場對公司產品的接受度、公司策略性重新定位計畫的成功與管理階層執行能力、公司持續進行的庫存降低計畫及其他成本降低措施的成功,以及公司不時在向美國證券交易委員會(SEC)提交之文件中所詳述的其他風險。

  • Joining us on the call today are Robert O'Leary, ICN's Chairman and Chief Executive Officer, Tim Tyson, President and Chief Operating Officer, Barry Bailey, Chief Financial Officer, Winnie Wu, Controller and Phillip Loberg, Treasurer. Now I would like to turn the call over to Robert O'Leary.

    今天與我們一同參與電話會議的有:ICN 董事長兼執行長 Robert O'Leary、總裁兼營運長 Tim Tyson、財務長 Barry Bailey、主計長 Winnie Wu,以及財務主管(Treasurer)Phillip Loberg。現在我想把電話會議交給 Robert O'Leary。

  • - Chairman and Chief Executive Officer

    - Chairman and Chief Executive Officer

  • Thank you, Greg. Thank you all for joining us here this morning. Our efforts in the fourth quarter continue to be focused on setting the stage and putting in place the building blocks that will drive our future growth. Our focus continues to be on improving our overall cost structure, divesting our noncore businesses and importantly restructuring our specialty pharmaceutical business.

    謝謝你,Greg。也謝謝各位今天早上加入我們。我們在第四季的努力仍然聚焦於為未來成長搭建舞台,並建立將推動未來成長的基礎要件。我們的重點仍在於改善整體成本結構、處分非核心業務,並且重要的是重整我們的專科藥品業務。

  • In a few short months, we've executed on a number of fronts. Our overall cost structure has been reduced by 21 million as we promised. We have stopped doing things that did not provide value. We have also initiated activities to drive future efficiencies and deliver on our commitment to rationalize the supply chain, including our manufacturing operations and to leverage our international buying power through a new centralized procurement initiative.

    在短短幾個月內,我們已在多個面向付諸執行。如同我們承諾的,我們已將整體成本結構降低 2,100 萬。我們已停止進行那些無法帶來價值的事項。我們也啟動了推動未來效率的相關活動,並履行我們對供應鏈合理化的承諾(包括製造營運),同時透過新的集中化採購計畫,運用我們的國際採購規模優勢。

  • In the fourth quarter we took additional steps in this program by taking action to dispose of all our manufacturing facilities in Hungary and the Czech Republic. We took an impairment charge of $76.6 million in the quarter as result of these and other actions. The impact of strategic decisions announced in November 2002 on ICN has been a significant and positive effect, a comparison of year-end results with and without discontinued operations shows a 10% improvement in the cost of goods sold, a previously mentioned $21 million reduction in the nonmanufacturing cost structure, and an improvement in net income by $32 million.

    在第四季,我們透過採取行動處分位於匈牙利與捷克共和國的所有製造設施,進一步推動此計畫。由於這些及其他行動,我們在本季認列了 7,660 萬美元的減損費用。2002 年 11 月宣布的策略決策對 ICN 產生了顯著且正面的影響;比較包含與不包含停業單位的年終結果可見:銷貨成本改善 10%、如前所述非製造成本結構降低 2,100 萬美元,且淨利增加 3,200 萬美元。

  • We have also made tangible progress on our divestiture plans. Today we announced that just six weeks into the first quarter we completed the sale of our U.S. and International Photonic businesses. In addition to being an important step in our repositioning efforts this divestiture helped us to avoid significant future commitments and obligations and an ongoing drain on our cash flows. We also have a nucleus of motivated buyers for our Biomedical business. The rest of our divestures are moving well and according to plan. With our noncore holdings position for divestiture, we are in a better position than ever to drive growth in the fundamental core business.

    我們在資產處分計畫上也取得了具體進展。今天我們宣布,在第一季開始僅六週內,我們已完成美國及國際光子(Photonic)業務的出售。除了是我們重新定位努力中的重要一步之外,這項處分也幫助我們避免未來重大的承諾與義務,以及對現金流的持續消耗。我們也已為生物醫學(Biomedical)業務建立了一批積極的潛在買家核心群。其餘的處分案進展順利,並按計畫推進。隨著非核心持股已就緒可供處分,我們比以往任何時候都更有條件推動核心基本業務的成長。

  • We are also well on our way towards building a world class management team to deliver on our new strategic vision. Over the last few months, we announced additional management team members in the areas of sales and marketing, manufacturing, supply chain and procurement. Important, among these leadership changes is the addition of Mr. Wes Wheeler, a proven performer, a superb leader who will oversee our North American operations which is our most important market. He will also lead the company's sales and marketing functions. We expect to continue rounding out our management team in the coming months.

    我們也正穩步打造一支世界級的管理團隊,以落實我們新的策略願景。過去幾個月,我們在銷售與行銷、製造、供應鏈與採購等領域宣布了新增的管理團隊成員。在這些領導層變動中,重要的一項是加入 Wes Wheeler 先生;他是經驗證的績效達成者與卓越領導者,將負責我們北美營運(這是我們最重要的市場)。他也將領導公司的銷售與行銷職能。我們預期在未來幾個月持續完善我們的管理團隊。

  • I am very pleased with the progress we have made and more importantly, the momentum we have established in setting the stage for future growth. This is an evolutionary process and not one that we can execute in a vacuum. Our focus in 2003 is on rebuilding ICN by driving efficiencies across all areas of the organization. In the long term, we believe our business will grow in ways that are attractive and add value to the organization, and to shareholders.

    我對我們所取得的進展感到非常滿意,更重要的是,我們已建立起為未來成長鋪陳的動能。這是一個循序演進的過程,而不是能在真空中執行的事情。我們在 2003 年的重點是透過推動組織各領域的效率提升,重建 ICN。長期而言,我們相信公司的業務將以具吸引力且能為組織與股東創造價值的方式成長。

  • With that now I would like to turn the call over to our President, Tim Tyson who will provide you with an overview of the building blocks we are putting in place to drive growth in the business. Tim?

    接下來我想把電話會議交給我們的總裁 Tim Tyson,他將為各位概述我們正在建立、用以推動業務成長的各項基礎要件。Tim?

  • - President and Chief Operating Officer

    - President and Chief Operating Officer

  • Thank you, Rob. Good morning to everyone. I'm very pleased to be here today. I look forward to meeting many of you over the coming year. The strategic plan we outlined last quarter was designed to create a leaner, more focused company with a strong emphasis on building shareholder value.

    謝謝你,Rob。各位早安。我很高興今天能在此與各位交流。我期待在接下來一年中與各位中的許多人見面。我們在上一季所概述的策略計畫,旨在打造一家更精實、更聚焦的公司,並強調提升股東價值。

  • In 2003, we expect to lay the foundation for substantial improvements in 2004 and beyond. We plan to build shareholder value by focusing on three important areas: Re-engineering our P&L, top line growth, and future innovations. A key objective of our strategic plan is to improve our overall cost structure and to focus on EBITDA performance. We're working on a number of plans designed to reduce inefficient investments and to bring our costs in line with industry averages.

    在 2003 年,我們預期將為 2004 年及其後的重大改善奠定基礎。我們計畫聚焦三個重要領域以提升股東價值:重塑我們的損益表(P&L)、營收成長(top line growth),以及未來創新。我們策略計畫的一項關鍵目標,是改善整體成本結構並聚焦 EBITDA 表現。我們正推動多項計畫,旨在降低低效率投資,並使成本水準與產業平均一致。

  • For example, the company currently has 30 plants around the world operating at about 5 to 15% capacity utilization. We're in the process of developing a manufacturing rationalization plan to deal with this issue, and we're going to do what's necessary over the next couple of years to rearrange our manufacturing capabilities to be more efficient. As Rob mentioned earlier, our decision to divest of all of our manufacturing facilities in Hungary and the Czech Republic represents the first step in this process. The upside in terms of operating efficiencies and cost savings will be significant. Our goal is to bring our cost of goods historically at 44% of sales in line with the industry average of 20%.

    例如,公司目前在全球有 30 座工廠,產能利用率約僅 5% 至 15%。我們正在制定製造合理化計畫以處理此問題,並將在未來幾年採取必要措施,重新配置我們的製造能力以提升效率。如 Rob 先前提到,我們決定處分位於匈牙利與捷克共和國的所有製造設施,代表此流程的第一步。在營運效率與成本節省方面的上行空間將相當可觀。我們的目標是將歷來約占銷售額 44% 的銷貨成本,拉近至產業平均約 20% 的水準。

  • Another area where we believe we can reduce our overall cost structure is SG&A spending, which has historically been greater than 55% of sales. We want to trend toward the industry average of about 35% by reducing SG&A while at the same time investing in effective promotional expenses to drive future growth.

    我們認為另一個可降低整體成本結構的領域是銷售、一般及行政(SG&A)支出;歷來其占銷售額比重高於 55%。我們希望在降低 SG&A 的同時,仍投資於有效的推廣費用以推動未來成長,並使其趨近產業平均約 35% 的水準。

  • As you heard Rob say earlier, we've already delivered $21 million in savings and we're looking for more opportunities. We're looking at everything because we want to make sure that we're spending our money in ways that actually build value for the organization and for our shareholders. Additionally, as Rob mentioned, we're putting a new centralized international procurement initiative in place that will leverage our buying power, there by reducing our costs and increasing our spend efficiency.

    如同各位先前聽到 Rob 所說,我們已實現 2,100 萬美元的節省,並正在尋找更多機會。我們檢視所有項目,因為我們要確保資金的使用方式確實能為組織與股東創造價值。此外,如 Rob 所提到,我們正在推行新的集中化國際採購計畫,以運用我們的採購規模優勢,從而降低成本並提升支出效率。

  • We're also looking at our tax rate, which is currently above 40%. We want to trend toward the industry average of 27% and are putting a tax strategy in place to help us achieve that goal. It's clear that while we expect to make good progress towards this goal in 2003, this is a multi-year effort that is intricately linked to our manufacturing rationalization process.

    我們也在檢視我們的稅率,目前超過40%。我們希望趨近於產業平均的27%,並正在制定稅務策略以協助我們達成該目標。很明顯,雖然我們預期在2003年朝此目標會有良好進展,但這是一項多年期的工作,且與我們的製造合理化流程緊密相連。

  • We are, in essence, re-engineering our P&L. We're examining all of our operations to make sure we stop doing things that don't make sense and start doing things that do. Put another way we're going to invest in areas that drive the business and stop investing in things that don't.

    本質上,我們正在重新設計我們的損益表(P&L)。我們正在檢視所有營運,以確保我們停止做不合理的事情,並開始做合理的事情。換句話說,我們將投資於能推動業務的領域,並停止投資於無法推動業務的事項。

  • We've also taken a look at our sales operations, as we believe incentive plans are a key driver of earnings. We recently implemented a new incentive model that is heavily weighted towards EBITDA performance. The new model provides greater incentives for better performance. People that deliver our plan will be rewarded significantly for delivering extraordinary performance to shareholders. Our short-term focus is on re-engineering the P&L, but we're also very focused on the future, as the future of our business is driving the top line.

    我們也檢視了我們的銷售營運,因為我們相信激勵計畫是獲利的關鍵驅動因素。我們近期導入了一個新的激勵模型,其權重高度偏向EBITDA表現。新模型對更佳績效提供更大的激勵。能達成我們計畫的人,若能為股東帶來卓越表現,將獲得顯著回饋。我們的短期重點是重新設計損益表(P&L),但我們也非常著眼於未來,因為我們業務的未來正在驅動營收(top line)。

  • We've taken a very close look at our markets and plan to focus on the major markets that represent approximately 85% of the worldwide pharmaceutical market, namely U.S., Germany, Spain, Italy, Poland, France, UK, Canada, and Mexico. Within these major pharmaceutical markets, we are developing a more global approach to commercializing products. In the United States, over the last three months, we refocused our efforts and increased our investments in marketing, promotional and training programs on three major products. We're already seeing results as all three products are growing.

    我們非常仔細地檢視了我們的市場,並計畫聚焦於約占全球藥品市場85%的主要市場,即美國、德國、西班牙、義大利、波蘭、法國、英國、加拿大與墨西哥。在這些主要藥品市場中,我們正在發展更全球化的產品商業化方法。在美國,過去三個月我們重新聚焦努力方向,並增加對三項主要產品的行銷、推廣與訓練計畫投資。我們已經看到成果,因為這三項產品都在成長。

  • Let me give you a few examples. One of our strongest products is Efudex®, which continues to be the market leading treatment for actinic keratosis. As is evidence but the total prescription data provide by INS, our market share grew from 49.7% in October 2002, to 51.2% in December 2002. This is a clear indication that our refocused efforts on promotional, marketing and training programs are working, especially when you consider the dynamics of this industry, where a 1/10th of a percentage point increase in market share represents a substantial improvement. Just to give you a perspective, the next most competitive product has 29.7% of the actinic keratosis market.

    我舉幾個例子。我們最強勢的產品之一是Efudex®,它仍是治療日光性角化症(actinic keratosis)的市場領先療法。INS提供的總處方資料顯示,我們的市占率從2002年10月的49.7%提升至2002年12月的51.2%。這清楚顯示我們重新聚焦於推廣、行銷與訓練計畫的努力正在奏效,尤其考量到本產業的動態:市占率每增加0.1個百分點就代表相當可觀的改善。提供一個參考,下一個最具競爭力的產品在日光性角化症市場的市占率為29.7%。

  • Another example of a product showing strong growth in the U.S. is Glyquin®, a prescription treatment for hyperpigmentation. Recent INS data indicates it has 14.7% of the U.S. market an increase of 2 percentage points from November of 2002, this 2 point increase is the result of a line extension we introduced in November via the introduction of Glyquin XM®, as well as our renewed focus on training, marketing and promotional programs.

    另一個在美國展現強勁成長的產品例子是Glyquin®,這是一種治療色素沉著過度(hyperpigmentation)的處方藥。近期INS資料顯示,其在美國市場的市占率為14.7%,較2002年11月增加2個百分點;這2個百分點的提升,來自我們於11月推出Glyquin XM®所帶來的產品線延伸,以及我們重新聚焦於訓練、行銷與推廣計畫。

  • Another growth product in the ICN portfolio is Kinerase®, a cosmeceutical available through dermatologists or other physician specialists for the treatment of sun damaged skin. Again, as a result of strong promotional activities in the fourth quarter 2002, Kinerase® unit sales increased 12.7% from the fourth quarter of 2001 and we're well-positioned to see future growth as we plan on introducing three new line extensions over the coming year. These are three examples of products we're selling in the major market in the United States that are performing well for us. There are many others, of course, but these three represent examples of the early successes of our efforts to focus on products with strong growth potential.

    ICN產品組合中另一項成長型產品是Kinerase®,這是一種可透過皮膚科醫師或其他專科醫師取得的藥妝品(cosmeceutical),用於治療日曬受損肌膚。同樣地,由於2002年第四季強力的推廣活動,Kinerase®的單位銷量較2001年第四季增加12.7%;而且我們已做好準備迎接未來成長,因為我們計畫在未來一年推出三項新的產品線延伸。以上是我們在美國這個主要市場中銷售且表現良好的三個產品例子。當然還有許多其他產品,但這三項代表我們聚焦於具強勁成長潛力產品之努力所取得的早期成功案例。

  • There also continuing growth in Latin America and Western Europe. In Latin America, Bedoyecta® grew 18% while Virazole® grew 23% and in Western Europe our sales grew 11% in 2002. In addition to focusing on specific products and geographies to drive top line growth, we are also looking at expanding our products in therapeutic areas where we currently have strength, potentially through the acquisition of products in the U.S. over the next year. Our focus will be on those products in which we have the in house expertise, background and knowledge, such as dermatologic and infectious disease products.

    拉丁美洲與西歐也持續成長。在拉丁美洲,Bedoyecta®成長18%,Virazole®成長23%;而在西歐,我們2002年的銷售成長11%。除了聚焦特定產品與地理區域以推動營收成長(top line growth)之外,我們也在評估擴展我們在目前具優勢的治療領域之產品,可能在未來一年透過在美國收購產品來達成。我們將聚焦於我們具備內部專業能力、背景與知識的產品,例如皮膚科與感染性疾病產品。

  • Our business is about products, however, we believe that having a product to sell in a specific geography is not enough to sustain growth. We have to have an innovation strategy, which means we have to have ways to bring products into the market. We currently have more than 600 products. We're going to closely evaluate the products we have and look at opportunities to bring these products to other markets either through reformulations or line extensions. The new team is actively involved and focused on internal discovery opportunities, and the new team will always been looking for other external opportunities to do partnerships, alliances or bringing in other products in the pipeline.

    我們的業務與產品息息相關;然而,我們相信僅在特定地區擁有可銷售的產品,並不足以維持成長。我們必須有創新策略,也就是必須有將產品導入市場的方法。我們目前擁有超過600項產品。我們將嚴格評估現有產品,並尋找機會透過重新配方或產品線延伸,將這些產品帶到其他市場。新團隊正積極投入並聚焦於內部研發探索機會,同時也會持續尋找外部機會,例如建立合作夥伴關係、策略聯盟,或引進其他在研產品(pipeline)中的產品。

  • Currently, our R&D investment in the specialty pharma business is less than 1%. Including Ribapharm® R&D is the 6% range whereas the industry average is between 13 and 15%. This continues to be an important area of our focus. These are the building blocks we're currently working on to drive growth, both bottom line and top line. We'll be providing you with updates on our progress throughout the year, so stay tuned.

    目前,我們在專科製藥業務的研發(R&D)投資低於1%。若包含Ribapharm®的研發,約在6%的區間,而產業平均介於13%至15%。這仍是我們重點關注的重要領域。這些是我們目前正在打造、用以推動成長的基礎要素,涵蓋獲利(bottom line)與營收(top line)。我們將在全年持續向各位更新進展,敬請期待。

  • We believe the upside opportunities at ICN are enormous and I'm very excited to be a part of the team that is going to make significant improvements. With that, I'd like to turn the call over to our CFO, Bary Bailey who will review fourth quarter and fiscal year-end results. Bary?

    我們相信ICN的上行機會非常龐大,我也非常興奮能成為將帶來重大改善之團隊的一員。接下來,我想把電話會議交給我們的財務長(CFO)Bary Bailey,由他回顧第四季與會計年度年終結果。Bary?

  • - Executive Vice President and Chief Financial Officer

    - Executive Vice President and Chief Financial Officer

  • Thank you, Tim. Good morning, everyone. At this time, I will be focusing on our quarterly results and will address our year-to-date results in the Q&A session. Revenues from continuing operations for the fourth quarter 2002 were $199 million as compared to the revenues of $194.2 million in the same period in the prior year, up 3%.

    謝謝你,Tim。各位早安。此刻我將聚焦於我們的季度業績,並會在問答(Q&A)環節說明我們的年初至今(year-to-date)結果。2002年第四季持續營運的營收為1.99億美元,相較於前一年度同期的1.942億美元,成長3%。

  • On a GAAP basis, we reported a net loss including nonrecurring and unusual items for the quarter of $100.7 million or $1.20 per diluted share compared with a net income of $33.5 million or 40 cents per diluted share in the same period in 2001. As we indicated we would last quarter, we recorded several nonrecurring and unusual items in the fourth quarter as a result of our strategic restructuring efforts. We have detailed these on table two.

    按GAAP基礎計算,我們本季(包含一次性與異常項目)報告淨損1.007億美元,或稀釋後每股虧損1.20美元;相較之下,2001年同期為淨利3,350萬美元,或稀釋後每股盈餘0.40美元。如同我們在上一季所指出的,因應我們的策略性重整努力,我們在第四季認列了數項一次性與異常項目。我們已在表二中詳列。

  • Nonrecurring and unusual charges in the fourth quarter as reflected on that table in the earnings release totalled $35 million or $22 million after taxes and minority interest or 26 cents per diluted share. Nonrecurring and unusual charges in the fourth quarter primarily included severance costs, additional environment clean up accruals, reimbursement of certain costs associated with our proxy contest and a write down of certain assets.

    如新聞稿中該表所示,第四季一次性與異常費用合計3,500萬美元,或扣除稅負與少數股權後為2,200萬美元,折合稀釋後每股0.26美元。第四季的一次性與異常費用主要包括資遣成本、額外的環境清理準備金、與我們委託書爭奪戰(proxy contest)相關之部分成本的補償,以及若干資產的減記。

  • One part of our strategy outlined last quarter was to divest our noncore businesses. These are businesses that do not fit into the company's new strategic direction. As you may recall, last quarter we segregated our Photonics business and [Cearcy] unit as discontinued operations. In the fourth quarter we added our manufacturing facilities in Central Europe, that is Hungary and the Czech Republic, as we began the process of rationalizing our manufacturing operations. We also added our Biomedicals business and our manufacturing and retail pharmacy operations in Russia to discontinued operations in the fourth quarter.

    我們在上一季所概述策略的一部分,是剝離我們的非核心業務。這些業務不符合公司新的策略方向。如各位所記得,上一季我們已將我們的光子(Photonics)業務及 [Cearcy] 單位劃分為停業部門。在第四季,隨著我們開始精簡製造營運的流程,我們也將中歐的製造設施(即匈牙利與捷克共和國)納入停業部門。我們亦在第四季將我們的生物醫藥(Biomedicals)業務,以及在俄羅斯的製造與零售藥局營運,納入停業部門。

  • The loss from these discontinued operations in the fourth quarter was $87.5 million or $1.04 per diluted share which includes an impairment charge of $76.6 million for those discontinued operations noted earlier. While these nonrecurring and unusual items had an impact on our fourth quarter results, they were all driven by our decision to focus on our core businesses. When you remove nonrecurring, unusual and extraordinary items, net income from continuing operations in the fourth quarter was $9.1 million or 11 cents per diluted share.

    第四季這些停業部門的虧損為 8,750 萬美元,或每股稀釋後 1.04 美元,其中包含先前提及之停業部門 7,660 萬美元的減損費用。雖然這些一次性及非經常性項目影響了我們第四季的業績,但其皆源自我們聚焦核心業務的決策。剔除非經常性、異常及非常項目後,第四季持續營運的淨利為 910 萬美元,或每股稀釋後 0.11 美元。

  • Operating income before nonrecurring and unusual items was $51.9 million in the fourth quarter, EBITDA before nonrecurring and unusual items was $65.1 million. This is down 31% as compared to EBITDA of $94.6 million in the fourth quarter of 2001.

    第四季在扣除非經常性及異常項目前的營業利益為 5,190 萬美元;在扣除非經常性及異常項目前的 EBITDA 為 6,510 萬美元。與 2001 年第四季 EBITDA 9,460 萬美元相比,下降 31%。

  • We continued to see strong performance from Ribapharm® who reported fourth quarter revenues of $83.9 million a 55% increase from the comparable period a year ago. The improvement at Ribapharm® was driven by higher royalties which reflect increased sales of Ribavirin® by Schering-Plough. As Ribapharm® told you in their call last week, we think that part of this increase was due to increased marketing on Schering's part in anticipation of another competitor entering the marketplace. We expect this will impact 2003 and therefore we do not expect the fourth quarter royalty revenue rate to be sustainable in 2003 for that reason.

    我們持續看到 Ribapharm® 的強勁表現,其第四季營收為 8,390 萬美元,較去年同期成長 55%。Ribapharm® 的改善主要來自較高的權利金,反映 Schering-Plough 的 Ribavirin® 銷售增加。如同 Ribapharm® 上週在電話會議中所提到,我們認為此增幅的一部分是因 Schering 預期另一家競爭者將進入市場而加強行銷所致。我們預期這將影響 2003 年,因此基於此原因,我們不預期第四季的權利金營收率在 2003 年能夠維持。

  • Our specialty pharmaceuticals business saw mixed performance with top line growth in Western Europe and strong operating performance in Latin America offset by a decrease in revenues in our other regions primarily due to the impact of our wholesale inventory reduction program in North America.

    我們的專科藥品業務表現好壞參半:西歐營收成長、拉丁美洲營運表現強勁,但被其他地區營收下滑所抵銷;下滑主要是因北美批發商庫存削減計畫的影響。

  • On that, let me say a few words with North America. If you'll look at table 3 of the press release, you will note in the fourth quarter North American revenues declined by $27.7 million or 70% over the same period in the previous year. The decline in sales primarily reflects the impact of the company's continuing program to reduce inventories at U.S. wholesalers. We believe we're about 60% of the way through our reduction plan and anticipate having the inventory issue resolved by the end of the second quarter.

    關於這點,讓我談幾句北美的情況。如果各位查看新聞稿的表 3,會注意到第四季北美營收較前一年同期減少 2,770 萬美元,或 70%。銷售下滑主要反映公司持續推動降低美國批發商庫存的計畫所帶來的影響。我們認為庫存削減計畫已完成約 60%,並預期在第二季末前解決庫存問題。

  • With respect to Western Europe, I do want to note that the operating loss in the 2002 fourth quarter was primarily attributable to asset write downs of $5.7 million. In the past, it has not been the practice of the company to provide a table that shows balance sheet information. We are, with this announcement, for the first time, sharing with you balance sheet highlights. We would like to note, as well, that this is a process that we will expect to further refine in our future quarterly announcements.

    就西歐而言,我確實要指出,2002 年第四季的營運虧損主要歸因於 570 萬美元的資產減記。過去公司並未慣例提供顯示資產負債表資訊的表格。我們在本次公告中,首次與各位分享資產負債表重點。我們也要指出,這是一個我們預期在未來季度公告中進一步精進的流程。

  • I want to now briefly review the balance sheet and other financial information. Cash at December 31, 2002 totalled $247.1 million compared with $319.4 million at year-end 2001. We believe that our cash on hand is sufficient to fund our ongoing operations for the foreseeable future. Accounts receivable were stable at $219.7 million at December 31, 2002 as compared to $219 million at year-end 2001 while inventory declined to $88.9 million from $91.1 million at the year-end 2001.

    我現在簡要回顧資產負債表及其他財務資訊。截至 2002 年 12 月 31 日,現金總額為 2.471 億美元,較 2001 年底的 3.194 億美元下降。我們相信手上現金足以支應可預見未來的持續營運資金需求。截至 2002 年 12 月 31 日,應收帳款維持穩定為 2.197 億美元,較 2001 年底的 2.190 億美元相近;存貨則由 2001 年底的 9,110 萬美元下降至 8,890 萬美元。

  • Long-term debt decreased to $482 million at December 31, 2002 down from $735 million at year-end 2001. The decrease in debt primarily reflects the redemption of the company's 8 3/4% senior notes in connection with the Ribapharm® IPO, as well as repurchases of $59.4 million of the company's convertible subordinated notes in open market transactions. Shareholders' equity decreased to $726 million at December 31, 2002 compared to $811 million at December 31, 2001. During 2002, the company repurchased 1.1 million shares of its common stock for $32 million in open market transactions under its stock repurchase plan.

    截至 2002 年 12 月 31 日,長期負債降至 4.82 億美元,較 2001 年底的 7.35 億美元下降。負債下降主要反映公司在 Ribapharm® IPO 相關交易中贖回 8 3/4% 優先票據,以及在公開市場交易中回購 5,940 萬美元的可轉換次順位票據。截至 2002 年 12 月 31 日,股東權益降至 7.26 億美元,較 2001 年 12 月 31 日的 8.11 億美元下降。2002 年期間,公司依其庫藏股計畫在公開市場交易中以 3,200 萬美元回購 110 萬股普通股。

  • Now, as promised, we would like to share with you our expectations for top and bottom line results for 2003. The past year has been one of considerable change for ICN, as we worked diligently to repair the business, reduce our wholesale inventory levels and set a new strategic direction for the company. As we look back, the wholesale inventory reduction plan has substantially positioned the company for improvements in 2003 and beyond. We expect that 2003 will continue to be a year of focus on building the business and laying a solid foundation for growth.

    現在,如先前承諾,我們想與各位分享我們對 2003 年營收與獲利(上、下線)結果的預期。過去一年對 ICN 而言變化甚鉅,我們努力修復業務、降低批發端庫存水位,並為公司設定新的策略方向。回顧而言,批發庫存削減計畫已大幅使公司具備在 2003 年及其後改善的條件。我們預期 2003 年仍將是專注於建構業務並為成長奠定堅實基礎的一年。

  • With that said, the following statements are based on current expectations. These statements are forward-looking and actual results may differ materially from current expectations. Our expectations for fiscal year 2003 revenues range between $770 million and $780 million. On a diluted basis, fiscal year-end 2003 EPS is expected to be between $1.20 and $1.25.

    在此情況下,以下陳述係基於目前的預期。這些陳述屬前瞻性,實際結果可能與目前預期有重大差異。我們對 2003 會計年度營收的預期區間為 7.70 億至 7.80 億美元。以稀釋後基礎計算,2003 會計年度每股盈餘(EPS)預期介於 1.20 至 1.25 美元。

  • We expect to resolve the wholesale inventory situation by the end of the second quarter with the majority of the impact being in the first quarter. And I must also note that because of the inventory situation and anticipated improvements in operations from efforts of the new management team, basis, fiscal year-end 2003 EPS is expected to be between $1.20 and $1.25. We expect to resolve the wholesale inventory situation by the end of the second quarter with the majority of the impact being in the first quarter.

    我們預期在第二季末前解決批發庫存狀況,且影響主要集中在第一季。我也必須指出,由於庫存狀況以及新管理團隊努力所帶來的營運改善預期,基礎上,2003 會計年度每股盈餘(EPS)預期介於 1.20 至 1.25 美元。我們預期在第二季末前解決批發庫存狀況,且影響主要集中在第一季。

  • And I must also note that because of the inventory situation and anticipated improvements in operation the impact being in the first quarter. And I must also note that because of the inventory situation and anticipated improvements in operations from efforts of the new management team, the earnings trend by quarter will not be linear, but rather weighted toward the second half of the year.

    我也必須指出,由於庫存狀況以及預期的營運改善,其影響將集中在第一季。我也必須指出,由於庫存狀況以及新管理團隊努力所帶來的營運改善預期,各季獲利趨勢不會呈線性,而是將偏重於下半年。

  • Just let me be blunt. Comparisons to the first quarter of 2002 will be particularly difficult as a result of the inventory initiative. Our expectations assume as well that Ribapharm® revenue will remain consistent with fiscal 2002, again impacted in the first part of 2003 by the increased sales in the fourth quarter of 2002 and that Ribapharm® will prevail with its litigation, additionally, we are expecting a tax rate of 38%. With that, I would now like to turn the call over to Rob for closing comments.

    我就直說吧。由於庫存措施,與 2002 年第一季相比將特別困難。我們的預期亦假設 Ribapharm® 營收將與 2002 會計年度一致;同時,2003 年前期將再次受到 2002 年第四季銷售增加的影響,並且 Ribapharm® 將在其訴訟中勝訴;此外,我們預期稅率為 38%。接下來,我想把電話會議交給 Rob 作結語。

  • - Chairman and Chief Executive Officer

    - Chairman and Chief Executive Officer

  • Thank you, Bary. Before we open up the call for questions and answers, I want to say a few words about a question I know is on all of your minds, the status of our investment in Ribapharm®. As you've heard us say before, this is a complex decision that requires careful analysis.

    謝謝你,Bary。在我們開放問答之前,我想先談幾句我知道各位都在關心的一個問題:我們對 Ribapharm® 的投資狀態。如同各位先前聽我們說過,這是一項複雜的決策,需要審慎分析。

  • We have not yet made a decision on Ribapharm® for three key reasons: First, you all know about the disruption caused by the change in management and the board of directors at Ribapharm®. Second, ICN and Ribapharm® recently reached agreement with Roche that put to rest and changed a plethora of issues that need to now be factored into our thinking. Third, the impact of the settlement between Schering and Three Rivers must be reviewed and analyzed.

    我們尚未就 Ribapharm® 作出決定,主要有三個關鍵原因:第一,各位都知道 Ribapharm® 因管理層與董事會更迭所造成的動盪。第二,ICN 與 Ribapharm® 近期與 Roche 達成協議,該協議已使許多問題告一段落並有所變更,而這些都需要納入我們目前的考量。第三,Schering 與 Three Rivers 之間和解的影響必須加以檢視與分析。

  • In light of these factors, combined with the complexities taking place in the hepatitis C market and the expected expansion of that market, as evidenced by recent IMS data and Roche's entry into the market, we have decided it is prudent and in the best interest of both the company and its shareholders to keep our options open until we get greater clarity on the outcome of these uncertainties. I want, however, to express my complete and unqualified confidence in the management, the scientists, the products, the science and the patents of Ribapharm®. We are continuing to evaluate all of our options, and we'll share more information with you on a timely basis when we are able.

    鑑於上述因素,再加上丙型肝炎市場正在發生的複雜情況以及該市場預期將擴張(近期 IMS 數據與 Roche 進入市場即為明證),我們認為在公司及股東的最佳利益下,於對這些不確定性的結果有更清晰的了解之前,保持選項開放是審慎之舉。不過,我想表達我對 Ribapharm® 的管理團隊、科學家、產品、科學研究以及專利,完全且毫無保留的信心。我們將持續評估所有選項,並在可行時及時與各位分享更多資訊。

  • I want to thank you all for your continued support of this company during a difficult period. Additionally, I would like to take this opportunity to thank, especially, our employees worldwide who, despite the challenges we faced in 2002, continued to perform above and beyond the call of duty, and are now looking forward optimistically to an exciting and successful 2003. And with that, I would like to open up the call to questions. Operator?

    我要感謝各位在這段艱難期間對本公司的持續支持。此外,我也想藉此機會特別感謝我們遍布全球的員工;儘管我們在 2002 年面臨挑戰,他們仍持續超越職責範圍地付出,並且如今正以樂觀態度期待一個令人振奮且成功的 2003 年。接下來,我想開放電話會議進入提問時間。接線員?

  • Thank you, Mr. O'Leary. Our Q&A session will be conducted electronically. If you would like to ask a question for our speakers, currently press the star key followed by the digit one on your touch-tone telephone. If you are joining us on a speaker phone, please release your mute function so your signal can reach our equipment. Once again, that will be star 1 to ask a question. And we will pause for just a moment to assemble our roster. Our first question comes from Richard Stover with Arnold & S. Bleichroeder.

    謝謝您,O'Leary 先生。我們的問答環節將以電子方式進行。若您想向我們的講者提問,請使用按鍵式電話按下星號鍵再按數字 1。若您使用擴音電話加入,請解除靜音功能,以便您的訊號能傳送至我們的設備。再次提醒,提問請按星號 1。我們將稍作停頓以整理提問名單。我們的第一個問題來自 Arnold & S. Bleichroeder 的 Richard Stover。

  • Yeah, that's difficult to say, it is Arnold & S. Bleichroeder. Good morning.

    是的,這有點難說,這裡是 Arnold & S. Bleichroeder。早安。

  • - Chairman and Chief Executive Officer

    - Chairman and Chief Executive Officer

  • Good morning, Rich.

    早安,Rich。

  • If I may ask, could you quantify your best estimate of the dollar impact on North American operations of the wholesaler reductions that occurred during 2002, and what that translates into for the first half of 2003? Secondly, with respect to your guidance and expectations on Ribapharm® revenues, to what extent have you factored into your thinking; one, the probable impact on pricing of Rebitol® as a result of Roche's pricing decision on [Opegus] and secondly the recently disclosed information from Schering-Plough of the unexpected weakness, at least to Roche of the Japanese hepatitis C franchise?

    如果可以請教,您能否量化您對 2002 年期間經銷商(批發商)減少庫存對北美營運造成的美元影響之最佳估計,以及這對 2003 年上半年意味著什麼?第二,關於您對 Ribapharm® 營收的指引與預期,您在思考中納入了哪些因素:第一,Roche 對 [Opegus] 的定價決策可能對 Rebitol® 定價造成的影響;第二,Schering-Plough 最近披露的資訊,即日本丙型肝炎業務(至少對 Roche 而言)出現了意外疲弱?

  • - Chairman and Chief Executive Officer

    - Chairman and Chief Executive Officer

  • I'm not going to promise you we're going to go through all of those. We'll take up half the time available for other people on the call, but we will get to a number of these now. I'll turn things over to Barry Bailey, but as people ask multiple questions, it will be our policy to answer the first question, and then ask you to go to the end of the cue for your second and third questions. We'll do the best we can with you, Rich, but I just want to establish that discipline if we could, please. Bary?

    我不會向你保證我們會把這些全部都講完。那會占用電話會議中其他人可用時間的一半,但我們現在會先回答其中幾個。我會把問題交給 Barry Bailey,不過當有人一次問多個問題時,我們的政策是先回答第一個問題,然後請你回到隊列末端再提第二與第三個問題。我們會盡力配合你,Rich,但我想先建立這個紀律,可以的話請配合。Bary?

  • - Executive Vice President and Chief Financial Officer

    - Executive Vice President and Chief Financial Officer

  • Yes. Good morning. Excuse me, Rick. The relative to the inventory situation, we've indicated we're about 60% of the way through that, and I believe in prior quarters we've indicated ranges of 10 to 15 million a quarter. But since this is also subject to litigation, I don't want to get into more detail than that. Suffice it to say we are comfortable at those previously indicated amounts. I will mention with respect to the Ribapharm® revenues, that they need -- you really need to ask the folks down at Ribapharm® relative to that.

    是。早安。不好意思,Rick。關於庫存情況,我們已表示目前大約完成了 60%,而我相信在先前的季度我們曾提到每季 1,000 萬到 1,500 萬的區間。但由於此事也涉及訴訟,我不想再深入更多細節。簡而言之,我們對先前所提到的金額水準感到放心。至於 Ribapharm® 的營收,我要提一下,你真的需要向 Ribapharm® 那邊的人詢問相關情況。

  • Okay.

    好的。

  • - Chairman and Chief Executive Officer

    - Chairman and Chief Executive Officer

  • Okay. Next question, please.

    好的。請下一個問題。

  • That will come from Michael Tong with Wachovia Securities.

    下一題來自 Wachovia Securities 的 Michael Tong。

  • Hi, good morning. Just one clarification question before we get into more details. I remember hearing you write about SG&A targeting to about 35% of product sales, and if that's correct, and based on backing out the Ribapharm® revenue implication of flat year-over-year, I would be looking at about $170 to $180 million in SG&A in '03 at about a $83 million quarterly run rate, how are you going to get there in '03?

    嗨,早安。在我們深入細節之前,我先問一個釐清問題。我記得聽到你們提到 SG&A 目標約為產品銷售的 35%;如果這是正確的,並且在扣除 Ribapharm® 營收「年對年持平」的影響後,我推算 2003 年的 SG&A 大約會是 1.70 億到 1.80 億美元,約等於每季 8,300 萬美元的運行率,你們打算如何在 2003 年達到那個水準?

  • - Chairman and Chief Executive Officer

    - Chairman and Chief Executive Officer

  • Tim Tyson?

    Tim Tyson?

  • - President and Chief Operating Officer

    - President and Chief Operating Officer

  • Yes. Thanks, Michael. As you know, any type of restructuring takes time, so we're not promising any of these directional results from where we are to the averages that we indicated in this year. So, we don't have, and didn't release specific targets on the year on those, but that is our focus on trending from where we are towards those averages. So, we're not going to get to that 35% this year.

    是。謝謝你,Michael。如你所知,任何形式的重整都需要時間,因此我們不會承諾在今年就能從目前狀況達到我們所提到的平均水準等方向性結果。所以,我們沒有、也未發布這些項目在全年層面的具體目標;但我們的重點是讓趨勢從目前狀況朝那些平均水準靠攏。因此,我們今年不會達到 35%。

  • Thank you.

    謝謝。

  • Moving on we'll hear from Alan Seymour with Colombia Management Group.

    接下來我們將聽取 Colombia Management Group 的 Alan Seymour 提問。

  • Hi. Kind of a similar question, although related to your R&D. What I'm really interested in is how you think about priorities for R&D, investment, and because obviously there is productivity issues related to that. Just throwing money at R&D usually doesn't work. So, could you kind of give me some sense as who how you evaluate R&D, and how you're likely to strategically invest in R&D?

    嗨。這有點像前一題,但與你們的研發(R&D)相關。我真正感興趣的是你們如何思考研發的優先順序與投資,因為顯然這牽涉到生產力問題。單純把錢砸在研發上通常行不通。所以,你能否大致說明你們如何評估研發,以及你們可能如何在策略上投資研發?

  • - Chairman and Chief Executive Officer

    - Chairman and Chief Executive Officer

  • Well, let me -- let me answer that in two ways, Alan. This is Robert O'Leary. I'll let Tim get to the heart of your question, but of course as you look at our consolidated statement, a lot of our R&D dollars are focused at Ribapharm®. And, you know, that's an independent management team and board of directors, and they're going to establish their own priorities how they allocate that money, and how they focus it.

    好,我——我用兩個角度回答你,Alan。我是 Robert O'Leary。我會讓 Tim 針對你的核心問題回答,但當然,當你看我們的合併報表時,我們相當多的研發支出是集中在 Ribapharm®。而且,你知道,那是一個獨立的管理團隊與董事會,他們會自行訂定優先順序,決定如何分配這筆資金以及如何聚焦。

  • I will tell you from our level, looking at the same data you're looking at, and from what we know from that public information, we're very, very pleased with the way that's happening, and particularly pleased with the continuing ramp up of focus of R&D dollars there. I am confident, I will tell you, that as we move forward, that the new management team and board are focused more than ever to make sure that the split between their available revenues between R&D spending and G&A is going to continue to be more heavily weighted to R&D.

    我可以告訴你,從我們的層級來看,基於你所看到的同樣數據,以及我們從公開資訊所了解的內容,我們對目前的進展感到非常、非常滿意,並且特別樂見那裡研發資金投入的持續加速提升。我也可以告訴你,我有信心,隨著我們往前推進,新管理團隊與董事會比以往任何時候都更專注於確保其可用營收在研發支出與一般及行政(G&A)之間的分配,將持續更偏重於研發。

  • So, I think we'll continue to see a strong investment there. ICN for its part, couldn't be more enthusiastic about supporting that direction. Now, as it relates to the specialty pharma business, let me call on my colleague, Tim Tyson.

    所以,我認為我們將會持續看到那方面有強勁的投資。ICN 就其本身而言,對於支持那個方向再熱情不過了。現在,至於專科製藥業務,讓我請我的同事 Tim Tyson 來說明。

  • - President and Chief Operating Officer

    - President and Chief Operating Officer

  • Thanks, Rob. Alan, I think there's two pieces one is tactical and the second is strategic. The tactical R&D focus will be on taking products that we have and trying to gain more value through reformulation and line extension. So, we're going to do investments on products that we believe have opportunities for growth by looking at reformulation and line extensions.

    謝謝你,Rob。Alan,我認為有兩個部分:一個是戰術層面,第二個是策略層面。戰術性的研發重點將放在把我們現有的產品,透過重新配方與產品線延伸來嘗試創造更多價值。因此,我們會在我們相信透過重新配方與產品線延伸具有成長機會的產品上進行投資。

  • On a strategic basis, we know, as others and all of you know, that the industry is based on innovation, and we're going to be focusing on innovation from a long-term standpoint, externally through alliances, partnerships and other opportunities and internally through our own discovery efforts.

    在策略層面上,我們知道——如同其他人以及在座各位都知道——這個產業是以創新為基礎,而我們將從長期角度聚焦於創新:對外透過結盟、合作夥伴關係及其他機會;對內則透過我們自身的研發探索工作。

  • - Chairman and Chief Executive Officer

    - Chairman and Chief Executive Officer

  • Let me just add, Alan, from my longer tenure here than Tim, but still brief, one of the things -- you might say, well that's what I expect a company to do. But the truth of the matter is that ICN's strategy historically has been almost solely dependent upon buying in. There has been virtually no, and that's being optimistic, life cycle management here of products. We have, in the short 90 days under Tim's leadership, already begun several aggressive initiatives.

    Alan,我再補充一下,雖然我在這裡的任期比 Tim 長一些,但也仍然不算久。有一件事——你可能會說,嗯,這正是我期望一家公司會做的。但事實是,ICN 過去的策略幾乎完全依賴外部收購。這裡幾乎沒有——而這麼說已經算樂觀了——對產品做生命週期管理。在 Tim 領導下短短 90 天內,我們已經開始了幾項積極的倡議。

  • That says two things. One we're going to have a capability we never had before, and second, we have a group of products here which we have not effectively yet mined or have not been mined over the last several years for these kinds of formulations and line extensions. We think there's some real attractive opportunity in it and we're going to be zeroing in on that like a laser.

    這說明兩件事。第一,我們將具備過去從未有過的能力;第二,我們這裡有一組產品,在過去幾年並未被有效地挖掘——或根本沒有被挖掘——以進行這類配方改良與產品線延伸。我們認為其中有非常吸引人的機會,我們將像雷射一樣精準聚焦在這上面。

  • Thank you.

    謝謝。

  • John Rasillory with State Street Research has our next question.

    State Street Research 的 John Rasillory 將提出下一個問題。

  • Thank you. You gave the three reasons for the complex decision of Ribapharm®. Can you give us any more flavor on issues we may be missing in terms of the Roche deal? And it seems to me that the big issue is obviously the patent in the U.S., if you wait for information on that, it would seem to me you wouldn't have much to say until we progress in the court case, which doesn't start until June.

    謝謝。你們提出了對 Ribapharm® 做出複雜決策的三個原因。就 Roche 交易而言,能否再多提供一些我們可能忽略的議題細節?而且在我看來,最大的問題顯然是美國的專利;如果要等待那方面的資訊,似乎在法院案件有進展之前你們也不會有太多可說的,而該案要到六月才開始。

  • - Chairman and Chief Executive Officer

    - Chairman and Chief Executive Officer

  • Well, I think you've done a great deal to answer your own question, John, and you folks are as smart as we are relative to the information that's available on the Roche strategy. I would say on your last point, however, there is a motion for summary judgment coming up at the end of March, and that is an important touchstone as well.

    John,我想你已經在很大程度上回答了你自己的問題,而就 Roche 策略可得資訊而言,你們各位和我們一樣聰明。不過就你最後一點我要說的是,三月底會有一項簡易判決(summary judgment)的動議,這也是一個重要的關鍵節點。

  • Beyond that comment, I am not prepared to comment on any time line relative to the decision. As you think back over our efforts in this regard, had we acted prematurely back in December or January, not withstanding the disruptions on the management and board activities, I do believe that we would be subject to some intense criticism from our shareholders today. We really believe we're going to need to wait and see, keep our options open and be very, very active in our analysis of these options.

    除了這點之外,我尚未準備好就該決策的任何時間表發表評論。回想我們在這方面的努力,如果我們在去年十二月或一月就過早採取行動——即便當時管理層與董事會活動出現干擾——我確實相信我們今天會遭到股東相當嚴厲的批評。我們真的認為需要等待觀察、保留選項,並且非常、非常積極地分析這些選項。

  • Obviously the generic case is a critical issue, but do not lose sight of the fact that the Roche settlement has been with ICN and Ribapharm® has settled many important issues. Thank you, John.

    顯然,學名藥案件是關鍵議題,但也不要忽視 Roche 與 ICN 的和解,以及 Ribapharm® 已經就許多重要議題達成和解。謝謝你,John。

  • Thank you.

    謝謝。

  • Once again, if you would like to ask a question, please press star one. We will now hear from Jerry Trepple with Wheaton Healthcare.

    再次提醒,如果您想提問,請按星號一。接下來我們將聽取 Wheaton Healthcare 的 Jerry Trepple。

  • Thank you. You had mentioned that from a manufacturing point of view you have 30 plants worldwide running at 5 to 15% capacity, I think you said. When you -- I'm unclear whether you're going to shut down or just sell the facilities in Hungary and the Czech Republic. What does that do to your utilization?

    謝謝。你提到從製造角度來看,你們在全球有 30 座工廠,產能利用率只有 5% 到 15%,我記得你是這麼說的。當你們——我不太清楚你們是要關閉還是只是出售匈牙利與捷克的設施。那對你們的產能利用率會有什麼影響?

  • - Chairman and Chief Executive Officer

    - Chairman and Chief Executive Officer

  • Those are incredible numbers. Let me turn to Tim Tyson on that.

    那些數字確實驚人。我把這個問題交給 Tim Tyson。

  • - President and Chief Operating Officer

    - President and Chief Operating Officer

  • Jerry, thanks for the question. Firstly, I would like to say the industry is not extremely great at capacity utilization and manufacturing, it is about 28 to30% from an industry standpoint, so we're not good, but the industry is not great. Our focus is on doing what's necessary to reduce the costs. The costs are in facilities, in the staffing, and in the cost of doing business at those operations. So yes, we will reduce the physical assets that we employ to increase our productivity and efficiency, and to reduce our cost of goods.

    Jerry,謝謝你的問題。首先我想說,整個產業在產能利用與製造方面並不是特別擅長;從產業角度看大約是 28% 到 30%,所以我們不算好,但產業也不算好。我們的重點是做必要的事情來降低成本。成本存在於設施、人員配置,以及在那些營運據點經營業務的成本。所以是的,我們將減少所使用的實體資產,以提升生產力與效率,並降低銷貨成本。

  • In Czech Republic and Hungary we have a facility in each of those two countries that we will be focusing on all of our operations that we look at rationalizing, we will be looking at taking care of our employees and trying to find other opportunities for them for employment through sales.

    在捷克與匈牙利,我們在這兩個國家各有一座設施;我們將把所有營運都納入合理化(rationalizing)的檢視範圍,同時我們也會照顧員工,並嘗試透過出售來為他們尋找其他就業機會。

  • So you're just going to shut the plant down is what you're saying?

    所以你的意思是你們要把工廠關掉?

  • - Executive Vice President and Chief Financial Officer

    - Executive Vice President and Chief Financial Officer

  • No. This is Bary Bailey. We're going to be selling those plants.

    不是。我是 Bary Bailey。我們會出售那些工廠。

  • Okay. Thank you.

    好的。謝謝。

  • - Executive Vice President and Chief Financial Officer

    - Executive Vice President and Chief Financial Officer

  • You're welcome.

    不客氣。

  • We will now hear from Matt Caplas with Quaker Capital Management.

    接下來我們將聽取 Quaker Capital Management 的 Matt Caplas。

  • Yes. I guess a question in terms of your guidance and how it relates to your view that Ribapharm® will be flat in '03 versus '02, is that at the net income line as well as revenue, because if it's at the net income line, and I guess I take 80% of that adjusted for the minority interest that would imply the rest of ICN, I guess basically broke even, am I doing the math right?

    是。我想問一個關於你們指引的問題,以及它如何對應你們認為 Ribapharm® 在 2003 年相較 2002 年將持平的看法:這是指淨利以及營收都持平嗎?因為如果是淨利也持平,而我再取其中 80% 並調整少數股權,那就意味著 ICN 其餘部分基本上是損益兩平;我的計算對嗎?

  • - Executive Vice President and Chief Financial Officer

    - Executive Vice President and Chief Financial Officer

  • No. With respect to Ribapharm®, what we are indicating, by the way this is Bary Bailey. We are indicating on a royalty basis, they are, we are anticipating about the same as last year. We didn't get into any further detail relative to their spending pattern.

    不是。就 Ribapharm® 而言,順帶一提,我是 Bary Bailey。我們所指的是在權利金(royalty)基礎上,我們預期大約與去年相同。至於他們的支出模式,我們沒有再進一步提供細節。

  • Okay. So to the extent their profitability, I guess decreases that would imply some profit at ICN then?

    好的。所以如果他們的獲利能力下降,那就表示 ICN 這邊會有一些獲利,對吧?

  • - Executive Vice President and Chief Financial Officer

    - Executive Vice President and Chief Financial Officer

  • Yes. We expect the specialty pharmaceutical business to be growing in its profitability and to be profitable. Absolutely.

    是的。我們預期專科製藥業務的獲利能力將成長,並且會是獲利的。絕對如此。

  • Okay. Good to hear.

    好的。很高興聽到。

  • - Executive Vice President and Chief Financial Officer

    - Executive Vice President and Chief Financial Officer

  • And more importantly, building a hell of a platform for the year beyond.

    而且更重要的是,為下一年度打造一個非常強大的平台。

  • Thank you.

    謝謝。

  • We will now hear from Ethan Mc Intyre with Q Investments.

    接下來我們將聽取 Q Investments 的 Ethan Mc Intyre。

  • Yeah, it's Ethan. I had a question on the asset sales --

    對,我是 Ethan。我有一個關於資產出售的問題——

  • - Chairman and Chief Executive Officer

    - Chairman and Chief Executive Officer

  • Ethan, could you speak up just a bit.

    Ethan,你可以把聲音再提高一點嗎。

  • On the asset sale, how much cash did you guys get? I know you didn't disclose the terms, but it would be helpful if you could.

    關於資產出售,你們拿到了多少現金?我知道你們沒有披露條款,但如果可以說明會很有幫助。

  • - Chairman and Chief Executive Officer

    - Chairman and Chief Executive Officer

  • Ethan, it's absolutely insignificant on the Photonic sales. This was mostly the divesting of a problem.

    Ethan,就 Photonic 的出售而言,金額完全微不足道。這主要是把一個問題業務剝離出去。

  • Okay what was the EBITDA burn, how about that then? On the business.

    好,那 EBITDA 的燒錢是多少?那這個呢?就那個業務而言。

  • - Chairman and Chief Executive Officer

    - Chairman and Chief Executive Officer

  • Ethan, we'll get back to you on that in just a minute.

    Ethan,我們一分鐘內再回覆你。

  • Okay. Thank you.

    好的。謝謝。

  • - Chairman and Chief Executive Officer

    - Chairman and Chief Executive Officer

  • Why don't we take the next question and we'll come back to Ethan when we have that.

    我們先進行下一個問題,等我們有資料再回到 Ethan 的問題。

  • Michael Stanski with Tudor Investments.

    Tudor Investments 的 Michael Stanski。

  • Yes. Could you just briefly go over the operating income areas? When we adjust Western Europe for the write-off and we look at pre-corporate expense we see some pretty high operating margins. Can you talk about how you sustain them and how you allocate corporate expense so we can get a sense of what the new business will look like over the next couple of years?

    是的。你們能否簡要說明一下營業利益的各個區塊?當我們把西歐的沖銷調整掉,並看沖銷公司費用前的數字時,我們看到相當高的營業利潤率。你們能談談如何維持這些利潤率,以及公司費用如何分攤,好讓我們了解未來幾年新業務會是什麼樣子嗎?

  • - Chairman and Chief Executive Officer

    - Chairman and Chief Executive Officer

  • We missed the first part of your question. Can you restate that?

    我們漏聽了你問題的前半段。你可以再說一次嗎?

  • Sure. When we look at the operating income disclosure that you gave us in Q4, we see, even adjusting for the Western Europe write-off of 5.7, we see some pretty healthy margins, I should say, by division.

    當然。我們看你們在第四季提供的營業利益揭露時,即使把西歐 5.7 的沖銷調整掉,我們仍看到各事業部的利潤率相當不錯。

  • How should we look at that going forward, especially relative to the high corporate expense in Q4, how that is over the next several quarters so we can get a sense of what the ongoing operating income margin and dollar level should be for core ICN operations?

    未來我們應該如何看待這個情況,特別是相對於第四季偏高的公司費用?接下來幾季會如何變化,讓我們能掌握核心 ICN 營運的持續性營業利益率與金額水準應該是多少?

  • - Executive Vice President and Chief Financial Officer

    - Executive Vice President and Chief Financial Officer

  • Well, Ethan, this is Bary Bailey. With respect to the strength in the regions, you should continue to expect that. Obviously caveated by the impact in the U.S. market on the continued inventory initiative, particularly in the first half of the year. With respect to the corporate run rate, we were impacted in the fourth quarter by additional legal expenses. We would expect that over the course of '03 we would continue to see that temper itself.

    嗯,Ethan,我是 Bary Bailey。就各區域的強勁表現而言,你應該可以預期會持續。當然要加上但書:美國市場仍在推動去化庫存的措施,特別是在上半年會有影響。至於公司費用的常態水準,我們第四季受到額外法律費用的影響。我們預期在 2003 年期間,這個影響會逐步緩和。

  • Can you put a dollar amount of what corporate expense line item is going forward?

    你能否給出未來公司費用這個科目的金額?

  • - President and Chief Operating Officer

    - President and Chief Operating Officer

  • Michael, if I'm just, if I can just say something. You can take through and bite through the pieces there, but I think what you need to take is that we're going to have a laser like focus on driving earnings in the business by focusing on the things that generate value.

    Michael,如果我可以補充一下。你可以把各個部分拆開來看,但我認為你需要掌握的是:我們會以雷射般的專注,透過聚焦於能創造價值的事項來推動業務獲利。

  • We've given you a trend that we're going from each one of the line items and that's what we're going to focus on and you should get a fairly good sense of how we're going to drop G&A to focus on the things that drive value.

    我們已經提供了各項目變動的趨勢,而這就是我們要聚焦的重點;你應該可以相當清楚地看出我們將如何降低 G&A,以專注在驅動價值的事情上。

  • - Executive Vice President and Chief Financial Officer

    - Executive Vice President and Chief Financial Officer

  • And with respect to outlining the individual components of '03, essentially Tim was saying that, we weren't going to break those components out.

    至於 2003 年各個組成項目的細項說明,Tim 的意思基本上是:我們不會把那些組成項目拆開揭露。

  • At this point I'd like to get back to Ethan with respect to the EBITDA burn at the Photonics business for '02, that was about $15 million.

    此刻我想回到 Ethan 關於 Photonics 業務在 2002 年的 EBITDA 燒錢問題,大約是 1,500 萬美元。

  • - Chairman and Chief Executive Officer

    - Chairman and Chief Executive Officer

  • Okay. Next question, please.

    好的。請下一個問題。

  • That will come from Sina Lunde with Cafe Financial.

    接下來是 Cafe Financial 的 Sina Lunde。

  • Hi. Good morning. Thanks for taking the question. On the cash flow, can you give us a guidance by the end of '03 with how does your cash flow look like, and in the guidance you gave for sales, does it include any acquisition of any specialty product or anything else like that?

    嗨。早安。謝謝讓我提問。關於現金流,你們能否提供到 2003 年底的指引,現金流大概會是什麼樣子?另外,你們給的銷售指引是否包含任何特殊產品的收購或其他類似事項?

  • - Chairman and Chief Executive Officer

    - Chairman and Chief Executive Officer

  • We'll take the last part of that question first.

    我們先回答問題的後半段。

  • - President and Chief Operating Officer

    - President and Chief Operating Officer

  • The answer is it does not include any acquisition. It's based on internal products that we currently have.

    答案是不包含任何收購。是以我們目前既有的內部產品為基礎。

  • Cash flow?

    現金流呢?

  • - Vice President and Treasurer

    - Vice President and Treasurer

  • Yes, this is Phil Loberg. Good morning. Thank you for the question. We are not giving any guidance on our cash flow. Our cash balance as of the end of February is approximately $330 million which is up from our year-end balance of approximately $250 million.

    是的,我是 Phil Loberg。早安。謝謝你的提問。我們不提供任何現金流指引。截至二月底,我們的現金餘額約為 3.30 億美元,高於年底約 2.50 億美元的餘額。

  • Thank you.

    謝謝。

  • Mike Hawthorne with Melon Bank is next.

    下一位是 Melon Bank 的 Mike Hawthorne。

  • I just wanted to find out if you guys still consider Ribapharm® as your most important asset?

    我只是想了解,你們是否仍認為 Ribapharm® 是你們最重要的資產?

  • - Chairman and Chief Executive Officer

    - Chairman and Chief Executive Officer

  • I think that's a -- that's a safe -- a safe assumption. It is a very valuable and critical asset to the company, but we have growing confidence and excitement about our specialty familiar business. Thank you, Mike.

    我想那是—那是個安全的—安全的假設。它對公司而言是非常有價值且關鍵的資產,但我們對我們的專科與熟悉藥品業務也越來越有信心並感到振奮。謝謝你,Mike。

  • Anything further Mr. Hawthorne?

    Hawthorne 先生,還有其他問題嗎?

  • No, that's it.

    沒有,就這樣。

  • Thank you. Once again, if you would like to ask a question, please press star one. We will now hear a follow-up question from Michael Tong.

    謝謝。再次提醒,如果您想提問,請按星號一。我們現在將聽取 Michael Tong 的追問。

  • Thank you, my follow-up has been answered.

    謝謝,我的追問已經被回答了。

  • - Chairman and Chief Executive Officer

    - Chairman and Chief Executive Officer

  • Thank you, Michael. If there are no further questions?

    謝謝你,Michael。如果沒有其他問題?

  • We do have a few more questions.

    我們還有幾個問題。

  • - Chairman and Chief Executive Officer

    - Chairman and Chief Executive Officer

  • Okay.

    好的。

  • Next follow up question is from Richard Stover with Arnold S. Bleishroeder.

    下一個追問來自 Arnold S. Bleishroeder 的 Richard Stover。

  • Thank you. Earlier in the year you had mentioned anticipation of generic competition from Estanon® and reduction of those inventories. What is the status of that competitive environment now for that product and what should we be looking for going forward?

    謝謝。今年稍早你們曾提到預期 Estanon® 會面臨學名藥競爭,以及將降低相關庫存。目前該產品的競爭環境狀況如何?未來我們應該關注什麼?

  • - President and Chief Operating Officer

    - President and Chief Operating Officer

  • Rick, Tim Tyson. Rick, the generic did come into the market place at the first of the year, and from a market share standpoint we're seeing a typical erosion, but there was a surprising activity, at the same time, there's been a spike in the volume of prescriptions, and so from our standpoint we have a level number of prescriptions, and you can see that in the IMS data.

    Rick,我是 Tim Tyson。Rick,學名藥在年初就已進入市場;從市占角度來看,我們看到典型的侵蝕,但同時也出現了令人意外的情況:處方量有一波激增,因此就我們而言,處方數量維持在持平水準,你可以在 IMS 數據中看到。

  • So, something happened to expand the market place there, and we're not sure what it is, but it seems to be coincidental with the approval of a NDA for an indication for a 30 milligram dose for treatment for nerve gas exposure for the U.S. military.

    所以,似乎有某些因素擴大了那裡的市場,我們不確定是什麼,但看起來可能與一項 NDA 核准同時發生:核准了一個 30 毫克劑量的適應症,用於美軍神經毒氣暴露的治療。

  • Is that all Mr. Stover?

    Stover 先生,就這些嗎?

  • That's all. Thank you.

    就這些。謝謝。

  • Moving on we'll hear from Tom Shinkle with Imperial Capital.

    接下來我們將聽取 Imperial Capital 的 Tom Shinkle。

  • Yes. Can you give us an indication of how much dividend capacity Ribapharm has to provide toward ICN the parent?

    是的。你們能否說明 Ribapharm 可提供給母公司 ICN 的股利能力大概有多少?

  • - Executive Vice President and Chief Financial Officer

    - Executive Vice President and Chief Financial Officer

  • This is Bary Bailey. With respect to dividend capacity, I don't think there, at least I haven't heard of any plans on Ribapharm® providing any dividends.

    我是 Bary Bailey。就股利能力而言,我認為至少我沒有聽說 Ribapharm® 有任何發放股利的計畫。

  • Is that by their direction or can you ask for dividends?

    那是他們自己的決定,還是你們可以要求他們發放股利?

  • - Executive Vice President and Chief Financial Officer

    - Executive Vice President and Chief Financial Officer

  • You'd have -- you'd have to ask them.

    你得——你得去問他們。

  • So you own 80% of it and they control the dividends?

    所以你擁有其中 80%,但他們控制股利?

  • - Executive Vice President and Chief Financial Officer

    - Executive Vice President and Chief Financial Officer

  • Yes.

    是。

  • Okay. Thank you.

    好的。謝謝。

  • We do have a follow-up question from Jerry Trepple.

    我們確實有 Jerry Trepple 的追問。

  • Um -- yeah, actually two. I just want to clarify what you said about Russia. I think you said you're going to basically discontinue the retail operations, you know, where does that leave the fairly significant manufacturing sector that you have there? And does your rationalization include adjustments to your U.S. sales force be that up or down?

    嗯——對,其實有兩個。我只是想釐清你剛才關於俄羅斯所說的。我想你說你們基本上會停止零售業務,你知道,那這樣你們在那邊相當可觀的製造部門會怎麼處理?另外,你們的精簡是否包含對美國銷售團隊的調整——不論是增加或減少?

  • - Chairman and Chief Executive Officer

    - Chairman and Chief Executive Officer

  • On the Russian question, Jerry, our announcement on November 7th indicated that we are selling all of our Russian operations, not only the resale pharmacy business, but all of the pharmaceutical business as well and our real estate. We do not intend to have an operation resident in Russia.

    關於俄羅斯的問題,Jerry,我們在 11 月 7 日的公告指出,我們正在出售我們在俄羅斯的所有營運,不僅是轉售藥局業務,也包括所有製藥業務以及我們的房地產。我們不打算在俄羅斯保留任何常駐營運。

  • Thank you.

    謝謝。

  • - Chairman and Chief Executive Officer

    - Chairman and Chief Executive Officer

  • And on the second part of your question, Tim Tyson's response.

    至於你問題的第二部分,由 Tim Tyson 回覆。

  • Yes, thanks, Rob.

    是的,謝謝你,Rob。

  • - President and Chief Operating Officer

    - President and Chief Operating Officer

  • On U.S. sales force, we have been focusing on and improving the sales force. We just replaced 20 of our representatives in the United States with more higher quality reps and we look at continued opportunities for expansion of that sales force based on size and structure analysis.

    關於美國銷售團隊,我們一直專注並改善銷售隊伍。我們剛在美國以更高素質的業務代表替換了 20 位代表,並且我們會基於規模與架構分析,持續評估擴編該銷售團隊的機會。

  • Okay, but there's no definitive plans one way or the other at this point?

    好的,但目前沒有任何明確的計畫,不論是哪個方向?

  • - President and Chief Operating Officer

    - President and Chief Operating Officer

  • No definitive plans?

    沒有明確計畫?

  • Yes.

    是。

  • - President and Chief Operating Officer

    - President and Chief Operating Officer

  • We have plans, we have added some 20 reps and we'll continue to add some additional reps in the states.

    我們有計畫;我們已新增大約 20 位代表,並且會在美國持續再增加一些代表。

  • Okay. Thank you.

    好的。謝謝。

  • We will now hear from Matt Caplas for a follow-up question.

    接下來我們聽 Matt Caplas 的追問。

  • Two sort of mini cash related questions. Do you have for '03 a depreciation amortization expectation and a cap ex expectation? And somewhat related, the net assets of the discontinued presumably have been written down to what you expect to realize, what's your time frame on that?

    兩個算是小型、與現金相關的問題。你們對 2003 年的折舊與攤銷(depreciation amortization)預期,以及資本支出(cap ex)預期是多少?另外有點相關的是,已終止業務的淨資產推測已被減記到你們預期可實現的金額,你們對此的時間表是什麼?

  • - Executive Vice President and Chief Financial Officer

    - Executive Vice President and Chief Financial Officer

  • Let me -- this is Bary Bailey. I'm going to answer the last part first. We anticipate divesting of all of the items we've moved to discontinue operations by the end of '03. And with respect to the balances, yes, we've adjusted those down down to what we believe to be the fair market value of those items. With the other I'm going to ask Mr. Loberg to follow-up.

    我——我是 Bary Bailey。我先回答最後一部分。我們預期在 2003 年底前處分我們已轉列為終止營運的所有項目。至於帳面餘額,是的,我們已將其調整(減記)至我們認為這些項目的公允市價。至於另一個問題,我會請 Loberg 先生接著回覆。

  • - Vice President and Treasurer

    - Vice President and Treasurer

  • You can he can expect the same run rate as last year approximately 50 million each for the duration of 2003.

    你可以預期與去年大致相同的水準,2003 年期間折舊攤銷約 5,000 萬、資本支出也約 5,000 萬。

  • 50 million cap ex even with all the excess facilities and all the stuff you're looking to get rid of?

    即使有那麼多閒置設施、以及你們打算處分的那些東西,資本支出還是 5,000 萬?

  • - Vice President and Treasurer

    - Vice President and Treasurer

  • No. The would be on a run rate base basis, it would be modified by any strategic activities that we may engage in for any major changes.

    不是。那是以常態化的 run rate 為基礎;若我們進行任何重大變動的策略性活動,該數字會相應調整。

  • I'm not sure I understand that.

    我不太確定我理解你的意思。

  • - Chairman and Chief Executive Officer

    - Chairman and Chief Executive Officer

  • Well, from time to time we're looking at strategic activities which could increase our decrease, for example, our cap ex strategy.

    嗯,我們不時會評估策略性活動,這些活動可能會增加或降低——例如——我們的資本支出策略。

  • Okay. I guess --

    好的。我想——

  • - Vice President and Treasurer

    - Vice President and Treasurer

  • Acquisitions, so on and so forth.

    併購等等。

  • Okay. I guess my only question is as relates to cap ex, if you're 5 to 15% utilization on 30 plants and looking to cut overhead, it seems odd that cap ex wouldn't go down.

    好的。我想我唯一的問題是,就資本支出而言,如果你們 30 座工廠的產能利用率只有 5% 到 15%,而且還打算削減間接費用,資本支出不下降似乎有點奇怪。

  • - Executive Vice President and Chief Financial Officer

    - Executive Vice President and Chief Financial Officer

  • This is Bary Bailey. With respect to that amount, what we're referencing is on continuing OPS, looking -- if you are going to look at it you would assume an ongoing run rate. Relative to guidance, we aren't really communicating that with respect to additions or subtractions over the course of '03, that is additional product acquisitions, additional other investments that are strategic.

    我是 Bary Bailey。就那個金額而言,我們指的是持續營運(continuing OPS)的常態水準——如果你要看它,你會假設是一個持續的 run rate。就財測而言,我們並未就 2003 年期間的增減提供溝通或指引;例如額外的產品收購、其他策略性投資等。

  • Okay. But that would be product acquisition as opposed to investing in property plant equipment or I.T. systems?

    好的。但那會是產品收購,而不是投資於不動產、廠房及設備或 I.T. 系統?

  • - Executive Vice President and Chief Financial Officer

    - Executive Vice President and Chief Financial Officer

  • Correct.

    正確。

  • Okay. Thank you.

    好的。謝謝。

  • Ethan Mc Intyre has a follow-up question as well.

    Ethan Mc Intyre 也有一個追問。

  • I just want to confirm. What was the cash number at the end of February?

    我只是想確認一下。2 月底的現金數字是多少?

  • - Executive Vice President and Chief Financial Officer

    - Executive Vice President and Chief Financial Officer

  • $330 million, approximately.

    約 3.30 億美元。

  • How did that go up so much?

    怎麼會增加這麼多?

  • - Executive Vice President and Chief Financial Officer

    - Executive Vice President and Chief Financial Officer

  • Well, we get our royalty -- Ribapharm® receives its royalty within 60 days following the end of the quarter.

    嗯,我們的權利金——Ribapharm® 會在季度結束後 60 天內收到權利金。

  • Would there have been any working capital just at ICN I am profits as well or was that all RNA?

    那 ICN 那邊是否也有任何營運資金的變動、或獲利的影響,還是全部都是 RNA?

  • - Executive Vice President and Chief Financial Officer

    - Executive Vice President and Chief Financial Officer

  • It wasn't all RNA, but a significant portion of it was the royalty receipt.

    不全是 RNA,但其中相當大一部分是權利金入帳。

  • Just on the cash restructuring charges, are we done with those now?

    關於現金重整費用(cash restructuring charges),我們現在已經結束了嗎?

  • - Executive Vice President and Chief Financial Officer

    - Executive Vice President and Chief Financial Officer

  • This is Bary Bailey. Um -- it is our expectation with respect to the restructuring charges we are done. Although, I would like to point out that as we look at continuing to rationalize our manufacturing facilities, we would expect that over the next year and into '04, that we could have additional charges with respect to that rationalization. They will be largely noncash and we view those as extremely positive.

    我是 Bary Bailey。嗯——就重整費用而言,我們預期已經告一段落。不過我想指出,當我們持續精簡製造設施時,我們預期在未來一年以及進入 2004 年,可能會因該精簡而產生額外費用。這些費用大多為非現金項目,我們認為這是非常正面的。

  • Fair enough. Thank you.

    可以理解。謝謝。

  • Moving on, we'll hear a follow-up question from Sina Lunde.

    接下來,我們聽 Sina Lunde 的追問。

  • Getting back to the cash question, I guess, I just want to get a better understanding. If you want to lay us down a plan, how do you want to spend this cash? I mean it looks like you're cash positive at this moment. Do you have a priority list of that?

    回到現金的問題,我想我只是想更清楚了解。如果你要給我們一個計畫,你們打算怎麼使用這些現金?我的意思是,你們目前看起來是現金淨流入。你們有優先順序清單嗎?

  • - Executive Vice President and Chief Financial Officer

    - Executive Vice President and Chief Financial Officer

  • This is Bary Bailey. With respect to '03 and that front, we're not providing specific guidance.

    我是 Bary Bailey。就 2003 年以及這方面而言,我們不提供具體指引。

  • Thank you.

    謝謝。

  • David Hoadley with Advent has the next question.

    Advent 的 David Hoadley 有下一個問題。

  • Hi. Could you tell me what the capital expenditure was in the quarter and also what cash flow from operations was in the quarter?

    你好。你能告訴我本季的資本支出是多少,以及本季營運活動現金流量是多少嗎?

  • - Executive Vice President and Chief Financial Officer

    - Executive Vice President and Chief Financial Officer

  • Yes. Capital expenditure -- I'm sorry what was the second part of the question?

    可以。資本支出——抱歉,問題的第二部分是什麼?

  • Cash flow from operations.

    營運活動現金流量。

  • - Executive Vice President and Chief Financial Officer

    - Executive Vice President and Chief Financial Officer

  • The capital expenditure for the quarter for continuing operations was $7 million. For the year it was $20 million. Discontinued operations it was $4 million for the quarter and $10 million for the year. And with respect to cash flow for the quarter --

    本季持續營運的資本支出為 700 萬美元。全年為 2,000 萬美元。終止營運方面,本季為 400 萬美元、全年為 1,000 萬美元。至於本季的現金流量——

  • - Vice President and Treasurer

    - Vice President and Treasurer

  • Yeah, we don't have the breakdown for operating cash flow for the quarter. I can give you a sense of the inflows and outflows for the quarter. Our cash balance increased from 250 to 255 during the quarter. The inflows were substantially the royalties of about 70-plus million and that was offset by various expenditures, taxes, cap ex, change of control payments, that's about 40 million in additional legal dividends and some acquisition spending of another 20 to 25 million.

    是的,我們沒有本季營運現金流量的拆分明細。我可以給你本季現金流入與流出的概況。我們的現金餘額在本季從 2.50 億增加到 2.55 億。流入主要是約 7,000 多萬的權利金,並被各項支出所抵銷:稅款、資本支出、變更控制(change of control)付款,另外還有約 4,000 萬的法律費用與股利,以及另外約 2,000 萬到 2,500 萬的併購支出。

  • Can you tell me if there's been any change in the intercompany balance between Ribapharm® and ICN since the end of the quarter?

    您能告訴我,自本季季末以來,Ribapharm® 與 ICN 之間的關係企業往來餘額是否有任何變化嗎?

  • - Executive Vice President and Chief Financial Officer

    - Executive Vice President and Chief Financial Officer

  • This is Bary. The answer is no.

    我是 Bary。答案是否定的。

  • And finally, I just want to check. The guidance of $1.20 to $1.25 that's after the minority interest of Ribapharm®?

    最後,我只是想確認一下。每股盈餘指引 1.20 至 1.25 美元是扣除 Ribapharm® 少數股權之後的嗎?

  • - Executive Vice President and Chief Financial Officer

    - Executive Vice President and Chief Financial Officer

  • That is correct.

    沒錯。

  • Okay. Thank you very much.

    好的。非常感謝。

  • - Executive Vice President and Chief Financial Officer

    - Executive Vice President and Chief Financial Officer

  • Thank you.

    謝謝。

  • We will now hear a follow-up question from Michael Stanski.

    接下來我們將聽取 Michael Stanski 的追問。

  • Two questions. Bary, net asset of discontinued ops are $154 million on the balance sheet. You've mentioned plans to monetize those assets, could we expect a similar item to be received over the next couple years as you sell those?

    兩個問題。Bary,資產負債表上列示的停業部門淨資產為 1.54 億美元。您提到有計畫將這些資產變現,未來幾年在出售這些資產時,我們是否可以預期會收到類似的款項項目?

  • - Executive Vice President and Chief Financial Officer

    - Executive Vice President and Chief Financial Officer

  • Michael, first of all, good morning. Like I've indicated earlier we've adjusted our discontinued ops to what we believe to be the fair market value.

    Michael,首先,早安。如我先前所指出的,我們已將停業部門調整至我們認為的公允市價。

  • And your plains to monetize those should we assume you can get some money out of that?

    那麼你們要將其變現的計畫,我們是否可以假設能從中拿到一些現金?

  • - Executive Vice President and Chief Financial Officer

    - Executive Vice President and Chief Financial Officer

  • As we sell it, that would -- being the cash person that I am, that is what I would expect.

    當我們出售時,那就會——以我這個重視現金的人來說——這就是我所預期的。

  • Can you comment on what you think the Russian operations are worth?

    您能評論一下您認為俄羅斯業務值多少嗎?

  • - Executive Vice President and Chief Financial Officer

    - Executive Vice President and Chief Financial Officer

  • No, I wouldn't want to specifically comment on any particular divestiture item.

    不,我不想就任何特定的資產處分項目做具體評論。

  • Second question. Your NOL balance, please?

    第二個問題。你們的 NOL 餘額是多少?

  • - Executive Vice President and Chief Financial Officer

    - Executive Vice President and Chief Financial Officer

  • The tax NOL?

    稅務 NOL(淨營業損失結轉)嗎?

  • Yes.

    是的。

  • - Executive Vice President and Chief Financial Officer

    - Executive Vice President and Chief Financial Officer

  • I can't comment on that right now. But it was a good try with those questions.

    我現在無法評論。不過這些問題問得不錯,算是一次很好的嘗試。

  • Thank you.

    謝謝。

  • Matt Caplas also has another question.

    Matt Caplas 也還有一個問題。

  • One last question. On the accrued restructuring expenses and any other sort of unusual items, what's the cash balance remaining there at year-end? Or what do you expect to spend this year?

    最後一個問題。關於應計重整費用以及其他任何類似的非經常性項目,年底時那裡剩餘的現金餘額是多少?或者你們預期今年會支出多少?

  • - Vice President and Treasurer

    - Vice President and Treasurer

  • Hi this is Phil Loberg. That amount is substantially complete vis-a-vis the totals during the year. We have just about 30 to 50 million still outstanding that will go out over the next 12 to 18 months.

    嗨,我是 Phil Loberg。就今年的合計金額而言,該項目基本上已接近完成。我們仍有約 3,000 萬到 5,000 萬美元尚未支付,將在未來 12 到 18 個月內付出。

  • And that's from continuing operations?

    而那是來自持續經營業務嗎?

  • - Vice President and Treasurer

    - Vice President and Treasurer

  • No. That's substantially from nonrecurring.

    不是。那主要是來自非經常性項目。

  • Okay. But, I guess my question is, is it captured in that net assets of business to be divested, or is it sort of a separate item?

    好的。不過,我想問的是:它是包含在「待處分業務淨資產」裡,還是算是單獨的項目?

  • - Executive Vice President and Chief Financial Officer

    - Executive Vice President and Chief Financial Officer

  • This is Bary. That -- it is -- it would be part of a separate accrual.

    我是 Bary。那——它是——會列在一項單獨的應計項目中。

  • Okay. Thank you.

    好的。謝謝。

  • - Chairman and Chief Executive Officer

    - Chairman and Chief Executive Officer

  • We'll take one last question, please.

    我們請最後一個問題。

  • That will be a follow-up question from Michael Tong.

    接下來是 Michael Tong 的追問。

  • Thanks for taking the question. I just want to make sure I heard correctly that cap ex for '02 was 20 million and your expectation of '03 is 50 million?

    謝謝讓我提問。我只是想確認我是否聽對了:2002 年的資本支出是 2,000 萬美元,而你們對 2003 年的預期是 5,000 萬美元?

  • - Executive Vice President and Chief Financial Officer

    - Executive Vice President and Chief Financial Officer

  • We haven't specifically commented on at least a detail level for '03. We indicated that '03 has not reflected any assumption around product acquisitions or major asset acquisitions so you need to make your own assumptions from there.

    我們尚未就 2003 年在細節層面做出具體評論。我們指出,2003 年並未納入任何產品收購或重大資產收購的假設,因此你需要在此基礎上自行做出假設。

  • The 20 is correct?

    那 2,000 萬是正確的?

  • - Executive Vice President and Chief Financial Officer

    - Executive Vice President and Chief Financial Officer

  • The 20 is correct.

    2,000 萬是正確的。

  • - Chairman and Chief Executive Officer

    - Chairman and Chief Executive Officer

  • Okay Michael?

    好的,Michael?

  • I thought in answer to one of the prior questions you said depreciation amortization and cap ex are roughly equal at '03 at about 50 I just wanted to make sure that was right.

    我記得在回答先前某個問題時,你說 2003 年折舊攤銷與資本支出大致相當,約為 5,000 萬,我只是想確認這是否正確。

  • - Executive Vice President and Chief Financial Officer

    - Executive Vice President and Chief Financial Officer

  • We indicated the depreciation typically runs about 50 and that's not significantly impacted by what's sitting in discontinued. On cap ex, all things being equal without special activities or special investments that's what the run rate has been and that's a fair rate to look at, but we're giving no guidance with regards to the impact of other strategic activities or changes in strategy.

    我們表示折舊通常約為 5,000 萬,而且不會因為停業部門中所包含的內容而受到顯著影響。至於資本支出,在沒有特殊活動或特殊投資、且其他條件相同的情況下,這一直是我們的常態水準,作為參考是合理的;但對於其他策略性活動或策略變更所帶來的影響,我們不提供任何指引。

  • Okay, thank you.

    好的,謝謝。

  • - Chairman and Chief Executive Officer

    - Chairman and Chief Executive Officer

  • Thank you, Michael. And at this time, I am going to bring the Q&A session to a close. I want to thank everyone for their time today. I also want to take this opportunity to acknowledge our new President and our new Chief Financial Officer and the impact they have had on the organization in the last 90 days.

    謝謝你,Michael。此時我將結束問答環節。感謝各位今天撥冗參與。我也想藉此機會肯定我們的新總裁與新財務長,以及他們在過去 90 天對組織所帶來的影響。

  • In these last 90 days, much of which has been taken up with the management and board distractions at Ribapharm®, this new management team has begun to fill the holes in the organization by attracting some incredible talent to ICN, accelerated our divestiture program, and, in fact, completed our first sale just six weeks into the new year, begun the process of closing excessive manufacturing capacity, and began the process of fundamentally changing the environment within the company to a performance oriented culture with the focus where it needs to be, on key products in major markets, and most importantly, has brought a new level of sophistication, energy and intensity to our financial and operational activities.

    在過去 90 天中,其中很大一部分時間都被 Ribapharm® 的管理層與董事會分心事項所占用,這個新的管理團隊已開始透過吸引一些非常傑出的人才加入 ICN 來補足組織缺口,加速我們的資產處分計畫,而且事實上在新年度開始僅六週就完成了第一筆出售,啟動關閉過剩製造產能的流程,並開始從根本上改變公司內部環境,建立以績效為導向的文化,將焦點放在應該放的地方——主要市場的關鍵產品——最重要的是,為我們的財務與營運活動帶來了更高層次的成熟度、活力與強度。

  • I want to close the call by repeating how pleased we are with the progress we have made. We have delivered on commitments made last November. We are excited about the new additions, and we are confident in our ability to deliver on our guidance for 2003 and before I close, it would be wrong of me not to acknowledge the patience that many of you out there have had with us and with this company, we promise that we will reward you for that patience and support. Thank you again, and we look forward to speaking with you in the near future.

    我想以重申我們對所取得進展的滿意來結束本次電話會議。我們已履行去年 11 月所做出的承諾。我們對新加入的成員感到振奮,並且有信心能夠達成我們對 2003 年的指引;在我結束之前,如果我不向在座許多人對我們以及這家公司所展現的耐心致意,那就不對了。我們承諾會回報各位的耐心與支持。再次感謝,並期待在不久的將來與各位再度交流。

  • Thank you. That does conclude today's teleconference. Thank you for your participation, at this time you may disconnect from the conference.

    謝謝。今天的電話會議到此結束。感謝各位的參與,現在您可以掛線離開會議。